Cypherpunk Technologies Inc. CYPH · Stock Open Cypherpunk Technologies Inc. in new tab

2.87 USD

Add to portfolio

P/E

4.73

EPS

0.63

P/B

2.30

ROE

-1.21

Beta

0.86

1M 6M YTD 1Y 2Y 5Y Max

Loading chart...

DCF valuation

Model fair value for Cypherpunk Technologies Inc. (CYPH)

Result

Sign in to run the valuation for CYPH.

Model fair value

–

Price

–

Model vs price

–

WACC – Terminal value PV – Σ PV of cash flows –

Fair value per share by discount rate (rows) and terminal growth (columns)
WACC \ g

Assumptions

Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–

Cypherpunk Technologies Inc. Analysis (CYPH)

Official Website Stock

Is Cypherpunk Technologies Inc. a good investment? Cypherpunk Technologies Inc. (CYPH) is currently trading at 2.87 USD.

In terms of valuation, the stock trades at a P/E ratio of 4.73. This relatively low multiple may signal that Cypherpunk Technologies Inc. is undervalued compared to historical market norms.

Earnings Schedule: Cypherpunk Technologies Inc. is expected to release its next earnings report on Nov. 11, 2026. The market consensus estimate for Forward EPS is -0.09.

Investor FAQ

Does Cypherpunk Technologies Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Cypherpunk Technologies Inc.?

Cypherpunk Technologies Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Nov. 11, 2026. The company currently has a trailing EPS of 0.63.

Company Profile

Cypherpunk Technologies Inc., a privacy technology company, implements a digital asset strategy anchored by Zcash in the United States. The company is involved in identifying, developing, investing in, acquiring, and building privacy-enhancing technologies; and accumulating digital assets, such as ZCash. It also develops biomarker-targeted antibody therapies for patients with cancer and other diseases comprising DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which has completed Phase 2 study for the treatment of colorectal cancer; and FL-501, a monoclonal antibody inhibiting the GDF-15 protein, which is in preclinical development to treat cancer cachexia, hyperemesis gravidarum and pregnancy-related nausea and vomiting, and other diseases associated with aging and frailty. The company was formerly known as Leap Therapeutics, Inc. and changed its name to Cypherpunk Technologies Inc. in November 2025. Cypherpunk Technologies Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Exchange Ticker

CYPH

NMS (United States) LPTX

Trades

Dividend History paid per year (USD)

No dividend history available.

Stock Splits

Split Date	Split Ratio to 1
June 21, 2023	1:10

Fundamentals

2026 © AllInvestView

Twitter YouTube Reddit Feature Requests Changelog Support Pricing Help

Support email: [email protected]

Terms of Service | Privacy Policy

Free Trackers · Dividend Apps · Tax Reporting · UK · Australia · Germany · Guides · Ticker Logos

Stock Directory · Financial Glossary · Portfolio Templates · Top Dividend Stocks · Investing in US · Investing in UK · Import Guides · Stock Comparison · Earnings Recaps

Data disclaimer: AIV (AllInvestView) assumes no liability for the information presented. Users are encouraged to exercise caution and carefully consider the accuracy, completeness, and relevance of the information provided.

It's important to remember that our website should complement your independent market research rather than replace it. The past performance of assets should not be regarded as a guarantee of future results. AllInvestView is not a registered investment advisor or broker/dealer, and the information presented here is for educational and informational purposes only. We value your trust and are committed to providing you with valuable market insights while emphasizing the importance of responsible decision-making in your investment journey.